Trial Profile

A Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients with Neuromyelitis Optica Lineage Disease

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 4406F (Primary)
Indications Neuromyelitis optica
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Bio-Thera Solutions

Most Recent Events

02 Jul 2025 Status changed from recruiting to discontinued, according to a Bio-Thera Solutions media release.
02 Jul 2025 According to a Bio-Thera Solutions media release, the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive interim analysis results. The company has decided to close patient enrollment ahead of schedule.
26 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com